Phathom Pharmaceuticals
Price & Volume
Stats
See more52W Range | $8.02-$18.31 |
Market Cap | $726.4M |
Shares Short | 12M |
Financials
See moreRevenue (12 Mos) | $239.6M |
Revenue Growth (YoY) | 88% |
Gross Profit (12 Mos) | $198.7M |
Diluted EPS | -$1.25 |
News
See moreYahoo Finance • 5 days ago
Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4
Yahoo Finance • last month
Phathom Pharma Completes Enrollment In Phase 2 PHalcon-EoE-201 For Eosinophilic Esophagitis
Yahoo Finance • 4 months ago
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight
Yahoo Finance • 4 months ago
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
About
CEO | Mr. Steven L. Basta M.B.A. |
Address | 100 Campus Drive, Florham Park, NJ, United States, 07932 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 371 |